LY294002 induces differentiation and inhibits invasion of glioblastoma cells by targeting GSK-3β and MMP
| dc.contributor.author | Cui, Hualei | |
| dc.contributor.author | Li, Yan | |
| dc.contributor.author | Lu, Huimin | |
| dc.contributor.author | Tian, Qi | |
| dc.date.accessioned | 2012-09-19T14:29:10Z | |
| dc.date.available | 2012-09-19T14:29:10Z | |
| dc.date.issued | 2012-09-19 | |
| dc.description.abstract | Glioblastomas are the most common and devastating primary tumors of the central nervous system, with high proliferative capacity, aggressive invasion, and resistance to conventional therapies. Differentiation therapy has emerged as a promising candidate modality. Here we show that the traditional phosphatidylinositol 3 kinase (PI3K) inhibitor LY294002 is capable of inducing differentiation of C6 glioblastoma cells characterized by morphological changes to astrocytic phenotype, increase in differentiation marker protein glial fibrillary acidic pro-tein and inhibition of proliferation. Small interfering RNA against glycogen synthase kinase-3β (GSK-3β) suppresses the induced-differentiation and invasiveness in C6 cells. LY294002 also inhibits MMP-9 expression and invasion of C6 cells, assembling the role of metalloprotease (MMP) inhibitor AG3340. Taken together, these findings suggest differentiation-inducing and invasion-inhibitory effectiveness of LY294002 in glioblastomas, most likely involving inhibition of GSK-3β and MMP respectively. | en |
| dc.identifier.issn | 1611-2156 | |
| dc.identifier.uri | http://hdl.handle.net/2003/29626 | |
| dc.identifier.uri | http://dx.doi.org/10.17877/DE290R-4914 | |
| dc.language.iso | en | de |
| dc.relation.ispartofseries | EXCLI Journal ; Vol. 11, 2012 | en |
| dc.subject | differentiation | en |
| dc.subject | glioblastoma | en |
| dc.subject | GSK-3β | de |
| dc.subject | invasion | en |
| dc.subject | LY294002 | de |
| dc.subject | MMP | de |
| dc.subject.ddc | 610 | |
| dc.title | LY294002 induces differentiation and inhibits invasion of glioblastoma cells by targeting GSK-3β and MMP | en |
| dc.type | Text | de |
| dc.type.publicationtype | article | de |
| dcterms.accessRights | open access | |
| eldorado.dnb.zdberstkatid | 2132560-1 |